Immunotherapy drug delays recurrence in kidney cancer patients

"KEYNOTE-564 is the first positive phase 3 study of an adjuvant immunotherapy in this setting and is a potential new standard of care," said Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, who led the study.

Immunotherapy drug delays recurrence in kidney cancer patients